• Immunovia published a peer-reviewed analysis in the Journal of Clinical Medicine on its PancreaSure blood test in hereditary or familial high-risk individuals.
• Results have already been presented through publication, based on a pooled retrospective analysis of two prior validation studies.
• The test showed it could identify early-stage pancreatic cancer in this high-risk group while correctly clearing most people without cancer.
• Performance appeared consistent across patients at risk due to inherited mutations versus family history, supporting the initial commercial target population.
• The data are intended to strengthen efforts to secure commercial insurer reimbursement for PancreaSure in the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovia AB published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.